Moderna (MRNA) Latest Stock Analysis Report – Oct 15, 2026, 4:00 PM ET
Updated Oct 15, 2026, 4:00 PM ET
MRNA jumps 4.5% to $236.50, a 52-week high, 3 up days in a row. Closed at $236.50, +4.51% vs the prior close of $226.30. Day range $217.02–$242.29, opened at $225.48.
MRNA daily analysis — what happened
A plain-English, data-only note written after every US trading day. Newest first; older days stay archived below.
Oct 15, 2026 — MRNA jumps 4.5% to $236.50, a 52-week high, 3 up days in a row
- Closed at $236.50, +4.51% vs the prior close of $226.30. Day range $217.02–$242.29, opened at $225.48.
- Volume was 17.29M shares, 0.8x its 50-day average of 22.50M.
- Price is +56.0% vs its 50-day average ($151.65) and +209.3% vs its 200-day average ($76.46).
- 52-week range $22.28–$242.29; today's close sits at 97% of that range, 2.4% below the 52-week high.
- That makes 3 straight gains.
Oct 14, 2026 — MRNA jumps 4.6% to $226.30, a 52-week high
- Closed at $226.30, +4.65% vs the prior close of $216.25. Day range $211.24–$227.09, opened at $217.49.
- Volume was 16.63M shares, 0.7x its 50-day average of 22.25M.
- Price is +52.9% vs its 50-day average ($148.05) and +200.0% vs its 200-day average ($75.43).
- 52-week range $22.28–$227.46; today's close sits at 99% of that range, 0.5% below the 52-week high.
Oct 13, 2026 — MRNA rises 1.2% to $216.25
- Closed at $216.25, +1.17% vs the prior close of $213.74. Day range $204.70–$218.48, opened at $207.63.
- Volume was 13.39M shares, 0.6x its 50-day average of 22.09M.
- Price is +49.5% vs its 50-day average ($144.66) and +190.4% vs its 200-day average ($74.46).
- 52-week range $22.28–$227.46; today's close sits at 95% of that range, 4.9% below the 52-week high.
Oct 12, 2026 — MRNA slides 5.0% to $213.74
- Closed at $213.74, -5.00% vs the prior close of $225.00. Day range $210.91–$227.46, opened at $224.50.
- Volume was 12.87M shares, 0.6x its 50-day average of 21.99M — lighter than usual.
- Price is +51.1% vs its 50-day average ($141.44) and +190.7% vs its 200-day average ($73.54).
- 52-week range $22.28–$227.46; today's close sits at 93% of that range, 6.0% below the 52-week high.
Oct 9, 2026 — MRNA jumps 14.2% to $225.00, a 52-week high, 3 up days in a row
- Closed at $225.00, +14.21% vs the prior close of $197.00. Day range $197.17–$225.00, opened at $199.00.
- Volume was 28.95M shares, 1.3x its 50-day average of 21.50M.
- Price is +62.7% vs its 50-day average ($138.26) and +209.8% vs its 200-day average ($72.63).
- 52-week range $22.28–$225.00; today's close sits at 100% of that range, at a new 52-week high.
- That makes 3 straight gains.
Oct 8, 2026 — MRNA ends flat (+0.3%) to $197.00
- Closed at $197.00, +0.26% vs the prior close of $196.48. Day range $192.71–$199.92, opened at $196.42.
- Volume was 37.40M shares, 1.8x its 50-day average of 20.84M.
- Price is +46.0% vs its 50-day average ($134.92) and +174.8% vs its 200-day average ($71.68).
- 52-week range $22.28–$212.22; today's close sits at 92% of that range, 7.2% below the 52-week high.
Oct 7, 2026 — MRNA jumps 4.8% to $196.48
- Closed at $196.48, +4.81% vs the prior close of $187.46. Day range $182.50–$197.69, opened at $183.65.
- Volume was 14.64M shares, 0.7x its 50-day average of 20.65M.
- Price is +48.8% vs its 50-day average ($132.07) and +177.3% vs its 200-day average ($70.86).
- 52-week range $22.28–$212.22; today's close sits at 92% of that range, 7.4% below the 52-week high.
Oct 6, 2026 — MRNA slides 7.8% to $187.46
- Closed at $187.46, -7.75% vs the prior close of $203.21. Day range $186.64–$212.22, opened at $202.09.
- Volume was 18.79M shares, 0.9x its 50-day average of 20.38M.
- Price is +45.0% vs its 50-day average ($129.25) and +167.7% vs its 200-day average ($70.04).
- 52-week range $22.28–$212.22; today's close sits at 87% of that range, 11.7% below the 52-week high.
Oct 5, 2026 — MRNA jumps 6.9% to $203.21
- Closed at $203.21, +6.95% vs the prior close of $190.01. Day range $185.90–$205.77, opened at $191.41.
- Volume was 19.31M shares, 1.0x its 50-day average of 20.08M.
- Price is +60.5% vs its 50-day average ($126.62) and +193.4% vs its 200-day average ($69.25).
- 52-week range $22.28–$208.90; today's close sits at 97% of that range, 2.7% below the 52-week high.
Oct 2, 2026 — MRNA rises 0.6% to $190.01
- Closed at $190.01, +0.57% vs the prior close of $188.94. Day range $183.28–$193.72, opened at $190.26.
- Volume was 10.29M shares, 0.5x its 50-day average of 19.97M — lighter than usual.
- Price is +53.7% vs its 50-day average ($123.63) and +177.9% vs its 200-day average ($68.39).
- 52-week range $22.28–$208.90; today's close sits at 90% of that range, 9.0% below the 52-week high.
MRNA latest news & SEC filings
Every SEC filing by or about MRNA in the last 120 days, explained in plain English. Updated daily, with a same-day refresh for new filings.
Oct 15, 2026 · 144 — Notice of proposed sale (Form 144)
Notice of proposed sale (Form 144) — an insider or affiliate plans to sell restricted or control shares
A notice of intent, not a completed sale. Any actual sale by a director or officer shows up later on Form 4.
Oct 14, 2026 · 144 — Notice of proposed sale (Form 144)
Notice of proposed sale (Form 144) — an insider or affiliate plans to sell restricted or control shares
A notice of intent, not a completed sale. Any actual sale by a director or officer shows up later on Form 4.
Oct 7, 2026 · 4 — Insider trade report (Form 4)
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Mock James M converted options/RSUs into 1,454 shares on Oct 5, 2026; now holds 60,829
- Mock James M had withheld for taxes 704 shares at $190.01 (≈$133.77K) on Oct 5, 2026; now holds 60,125
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Oct 5, 2026 · 3 — Initial insider ownership statement (Form 3)
Initial insider ownership statement (Form 3) — a new director, officer or 10% owner disclosed their holdings
Sep 30, 2026 · 8-K — Current report
Current report — a filing companies must make within 4 business days of a major event
- Item 5.02 — Change in directors or officers (appointment, departure or pay).
- Item 7.01 — Released information under Regulation FD (e.g. a presentation or press release).
Sep 16, 2026 · 4 — Insider trade report (Form 4)
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Hoge Stephen converted options/RSUs into 76,453 shares at $12.21 (≈$933.49K) on Sep 14, 2026; now holds 1,566,152
- Hoge Stephen sold 40,294 shares at $144.13 (≈$5.81M) on Sep 14, 2026; now holds 1,525,858
- Hoge Stephen converted options/RSUs into 76,452 shares at $12.21 (≈$933.48K) on Sep 15, 2026; now holds 1,602,310
- Hoge Stephen sold 40,281 shares at $146.07 (≈$5.88M) on Sep 15, 2026; now holds 1,562,029
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Sep 15, 2026 · 144 — Notice of proposed sale (Form 144)
Notice of proposed sale (Form 144) — an insider or affiliate plans to sell restricted or control shares
A notice of intent, not a completed sale. Any actual sale by a director or officer shows up later on Form 4.
Sep 1, 2026 · 8-K — Current report
Current report — a filing companies must make within 4 business days of a major event
- Item 1.01 — Signed a material agreement.
- Item 2.03 — Took on a new material debt or financial obligation.
- Item 3.02 — Sold unregistered shares.
- Item 8.01 — Reported other events the company considers important.
Aug 12, 2026 · SCHEDULE 13G — Passive stake (13G)
Passive stake (13G) — an investor reported owning more than 5%
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 6, 2026 · SCHEDULE 13G/A — Update to a passive 5%+ stake (13G)
Update to a passive 5%+ stake (13G)
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Jul 31, 2026 · 10-Q — Quarterly report (unaudited financial statements for the quarter)
Quarterly report (unaudited financial statements for the quarter)
Quarter ended Jun 30, 2026:
- Revenue: $145.00M (prior year $142.00M) (+2.1% vs Jun 30, 2025)
- Net income: -$782.00M (prior year -$825.00M) (loss narrowed vs Jun 30, 2025)
- Diluted EPS: -$1.97 (prior year -$2.13) (loss narrowed vs Jun 30, 2025)
Jul 31, 2026 · 8-K — Current report
Current report — a filing companies must make within 4 business days of a major event
- Item 2.02 — Reported results of operations (earnings release).
This is a results-day filing: the earnings press release is attached as an exhibit.
Jul 24, 2026 · SCHEDULE 13G/A — Update to a passive 5%+ stake (13G)
Update to a passive 5%+ stake (13G)
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Jul 8, 2026 · 8-K — Current report
Current report — a filing companies must make within 4 business days of a major event
- Item 5.02 — Change in directors or officers (appointment, departure or pay).
- Item 7.01 — Released information under Regulation FD (e.g. a presentation or press release).
Things to know before you trade MRNA
- Last results release: Jul 31, 2026 (8-K Item 2.02). Previous ones: May 1, 2026, Feb 13, 2026, Jan 12, 2026. Based on that rhythm, the next report is likely around Oct 30, 2026 — an estimate, not a confirmed date.
- How much it moves: over the last 20 sessions the average daily move was 4.54% (largest 14.2%). That is a volatile stock.
- Liquidity: about 18.29M shares (≈$4.33B) trade per day on average.
- 52-week position: $236.50 vs a range of $22.28–$242.29 (97% of the range).
- Dividends: no cash dividends in the last 2 years.
- Splits: none in the last 2 years.
- Insider trades (Form 4, last 12 months, recent 25 shown): 0 open-market buys, 19 sales; latest: Stephen Hoge sold 40,281 shares on Sep 15, 2026.
- Latest filings: 8-K Sep 30, 2026; 8-K Sep 1, 2026; 10-Q Jul 31, 2026.
- Share count: 399.24M shares outstanding (Jul 24, 2026), +2.6% vs a year earlier.
- Listing: Nasdaq · industry: Biological Products, (No Diagnostic Substances).
MRNA market data (last 20 sessions)
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 15, 2026 | 225.48 | 242.29 | 217.02 | 236.50 | 17.29M |
| Oct 14, 2026 | 217.49 | 227.09 | 211.24 | 226.30 | 16.63M |
| Oct 13, 2026 | 207.63 | 218.48 | 204.70 | 216.25 | 13.39M |
| Oct 12, 2026 | 224.50 | 227.46 | 210.91 | 213.74 | 12.87M |
| Oct 9, 2026 | 199.00 | 225.00 | 197.17 | 225.00 | 28.95M |
| Oct 8, 2026 | 196.42 | 199.92 | 192.71 | 197.00 | 37.40M |
| Oct 7, 2026 | 183.65 | 197.69 | 182.50 | 196.48 | 14.64M |
| Oct 6, 2026 | 202.09 | 212.22 | 186.64 | 187.46 | 18.79M |
| Oct 5, 2026 | 191.41 | 205.77 | 185.90 | 203.21 | 19.31M |
| Oct 2, 2026 | 190.26 | 193.72 | 183.28 | 190.01 | 10.29M |
| Oct 1, 2026 | 186.61 | 201.00 | 186.01 | 188.94 | 15.44M |
| Sep 30, 2026 | 186.55 | 196.83 | 184.58 | 192.57 | 20.65M |
| Sep 29, 2026 | 197.78 | 208.90 | 190.00 | 203.46 | 13.28M |
| Sep 28, 2026 | 195.15 | 199.82 | 189.10 | 197.28 | 13.36M |
| Sep 25, 2026 | 195.35 | 202.67 | 192.51 | 198.88 | 13.95M |
| Sep 24, 2026 | 180.60 | 195.71 | 180.39 | 194.82 | 16.61M |
| Sep 23, 2026 | 183.40 | 192.31 | 181.30 | 182.11 | 17.73M |
| Sep 22, 2026 | 168.50 | 187.20 | 168.30 | 182.56 | 24.03M |
| Sep 21, 2026 | 161.05 | 176.86 | 159.06 | 172.94 | 21.02M |
| Sep 18, 2026 | 158.35 | 159.79 | 150.26 | 154.04 | 20.23M |
About Moderna
Moderna (MRNA) is listed on the Nasdaq and classified by the SEC under “Biological Products, (No Diagnostic Substances)”. Its business address is in CAMBRIDGE, MA. State of incorporation: DE. Fiscal year ends December 31. SEC CIK 1682852.
MRNA board of directors & executives
From SEC Form 3/4/5 insider filings made in the last 12 months (date = latest filing).
Directors
| Name | Role | Latest filing |
|---|---|---|
| Noubar Afeyan | Director | May 22, 2026 |
| Stephane Bancel | Chief Executive Officer | Aug 7, 2026 |
| Sandra Horning | Director | May 8, 2026 |
| Abbas Hussain | Director | May 8, 2026 |
| Michael R. Mcdonnell | Director | Jul 10, 2026 |
| Elizabeth G Nabel | Director | May 8, 2026 |
| Francois Nader | Director | May 8, 2026 |
| David M. Rubenstein | Director | May 8, 2026 |
| Elizabeth E Tallett | Director | May 8, 2026 |
Executive officers
| Name | Title | Latest filing |
|---|---|---|
| Stephane Bancel | Chief Executive Officer | Aug 7, 2026 |
| Soria Ester Banque | Chief Commercial Officer | Jul 7, 2026 |
| Stephen Hoge | President | Sep 16, 2026 |
| Shannon Thyme Klinger | Chief Legal Officer | Sep 8, 2026 |
| James M Mock | Chief Financial Officer | Sep 14, 2026 |
Recent insider buys & sales
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Sep 15, 2026 | Stephen Hoge | Sale | 40,281 | $146.07 |
| Sep 14, 2026 | Stephen Hoge | Sale | 40,294 | $144.13 |
| Sep 10, 2026 | James M Mock | Sale | 15,000 | $134.49 |
| Sep 10, 2026 | James M Mock | Sale | 19,836 | $134.49 |
| Sep 1, 2026 | Shannon Thyme Klinger | Sale | 3,471 | $139.95 |
| Aug 5, 2026 | Stephane Bancel | Sale | 124,838 | $56.96 |
| Aug 5, 2026 | Stephane Bancel | Sale | 187,044 | $58.79 |
| Aug 5, 2026 | Stephane Bancel | Sale | 147,473 | $56.21 |
| Aug 5, 2026 | Stephane Bancel | Sale | 39,891 | $58.12 |
| Jul 15, 2026 | Stephen Hoge | Sale | 53,336 | $67.60 |
| Jun 15, 2026 | Stephen Hoge | Sale | 53,336 | $51.37 |
| Jun 4, 2026 | Shannon Thyme Klinger | Sale | 3,471 | $50.00 |
| May 21, 2026 | Noubar Afeyan | Sale | 9,263 | $46.84 |
| May 15, 2026 | Stephen Hoge | Sale | 53,336 | $48.40 |
| May 1, 2026 | Abbas Hussain | Sale | 5,682 | $46.63 |
MRNA financials (annual, from XBRL filings)
| Fiscal year end | Revenue | Net income | Diluted EPS | Operating cash flow |
|---|---|---|---|---|
| Dec 31, 2025 | $1.94B | $-2.82B | -7.26 | $-1.87B |
| Dec 31, 2024 | $3.24B | $-3.56B | -9.28 | $-3.00B |
| Dec 31, 2023 | $6.85B | $-4.71B | -12.33 | $-3.12B |
| Dec 31, 2022 | $19.26B | $8.36B | 20.12 | $4.98B |
| Dec 31, 2021 | $18.47B | $12.20B | 28.29 | $13.62B |
Latest balance sheet: total assets $10.96B, total liabilities $4.20B, cash $1.72B (as of Jun 30, 2026).
MRNA earnings / results-day log
| Date | Filing | Close that day |
|---|---|---|
| Jul 31, 2026 | 8-K Item 2.02 (results) | $54.82 |
| May 1, 2026 | 8-K Item 2.02 (results) | $45.37 |
| Feb 13, 2026 | 8-K Item 2.02 (results) | $42.23 |
| Jan 12, 2026 | 8-K Item 2.02 (results) | $33.84 |
| Nov 6, 2025 | 8-K Item 2.02 (results) | $24.33 |
| Aug 1, 2025 | 8-K Item 2.02 (results) | $27.60 |
| May 1, 2025 | 8-K Item 2.02 (results) | $27.03 |
| Feb 14, 2025 | 8-K Item 2.02 (results) | $32.99 |
| Jan 13, 2025 | 8-K Item 2.02 (results) | $35.15 |
| Nov 7, 2024 | 8-K Item 2.02 (results) | $50.28 |
| Aug 1, 2024 | 8-K Item 2.02 (results) | — |
| May 2, 2024 | 8-K Item 2.02 (results) | — |
Related stocks · Biological Products, (No Diagnostic Substances)
Amgen (AMGN)Gilead Sciences (GILD)Twist Bioscience (TWST)Argenx Se (ARGX)Biogen (BIIB)Halozyme Therapeutics (HALO)Revolution Medicines (RVMD)Recursion Pharmaceuticals (RXRX)ImmunityBio (IBRX)Repligen (RGEN)
Popular today
Micron Technology (MU)Spdr S&P 500 Etf (SPY)Nvidia (NVDA)Sandisk (SNDK)AMD (AMD)Space Exploration Technologies (SPCX)Intel (INTC)Apple (AAPL)Microsoft (MSFT)Meta Platforms (META)Broadcom (AVGO)Tesla (TSLA)
More on MRNA
Information only, not investment advice. BuyMeWhiskey is not a registered investment adviser or broker-dealer; nothing here is a recommendation to buy, sell or hold any security, and there are no price targets. Data comes from SEC EDGAR filings and public end-of-day market data and may be delayed or contain errors. Verify with the company's filings before making decisions. Prices: end-of-day data as of Oct 15, 2026, 4:00 PM ET. Filings: SEC EDGAR. Updated after every US trading day.